US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca's Q1 2025 Financial Results
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 10 Next >